FDA: Generic antidepressant for Wellbutrin is ineffective

Published On: Oct 09 2012 12:25:53 PM EDT
Updated On: Oct 09 2012 12:26:45 PM EDT

The U.S. Food and Drug Administration said new data indicate that the generic version of the popular antidepressant Wellbutrin is not equivalent to the original drug manufactured by GlaxoSmithKline.

Budeprion XL 300 mg, or bupropion hydrochloride extended-release tablets, are manufactured by Impax Laboratories Inc and marketed by Teva Pharmaceuticals USA Inc.

The FDA, in a notice posted on its website on Wednesday, said it has changed the therapeutic equivalence rating for the product in the agency's Approved Drug Products with Therapeutic Equivalence Evaluations to show that Budeprion XL 300 mg fails to demonstrate therapeutic equivalence to Wellbutrin XL 300 mg. Concerns over its effectiveness date back to 2007 when patients started complaining of multiple side effects, including headaches, anxiety and insomnia.

Impax has requested that the FDA withdraw approval of budeprion XL 300 mg extended-release tablets, the FDA said. Impax and Teva have stopped shipping the product, the agency said.

Read:

Is your medicine making you fat?

FDA unveils new device to detect counterfeit drugs

Drugs, therapy can help treat depression

Comments

The views expressed below are not those of Click On Detroit, WDIV, or its affiliated companies. By clicking on "Post," you acknowledge that you have read the Terms of Service and your comment is in compliance with such terms. Readers, please help keep this discussion respectful and on topic by flagging comments that are offensive or inappropriate (hover over the commenter's name and you'll see the flag option appear on right side of that line). And remember, respect goes both ways: Tolerance of others' opinions is important in a free discourse. If you're easily offended by strong opinions, you might skip reading comments entirely.

blog comments powered by Disqus